The data suggests that TR4 increases the PCa metastasis through the signaling of miR-373-3p, and using the TR4 antagonist, TR4-siRNA, or miR-373-3p may become a new potential therapeutic approach to better suppress PCa metastasis (25). Here, NR2C2 is linked to posterior cortical atrophy.